Skyhawk's proprietary platform revolutionizes disease treatment by developing small molecule therapeutics that modify RNA expression
June 1, 2026
Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease
Twelve-month findings showed improvement in Composite Unified Huntington's Disease Rating Scale (cUHDRS) scores from baseline of +0.38, compared to an expected decline of -0.92 points in propensity score-weighted natural history analyses of symptomatic patients
Skyhawk reports positive first results in Huntington's patients for oral drug
Skyhawk Therapeutics released its first trial data in Huntington’s disease patients on Wednesday, demonstrating early and competitive levels of efficacy in an area that’s seen a long list of failures by other drug developers.
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral dose
Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
SKY-1214, an IND-ready first-in-class FANCL/FANCI RNA splicing modulator, demonstrates tumor growth inhibition and regression to undetectable levels in NHL and difficult-to-treat MM xenograft mouse models
Skyhawk Therapeutics to Present Additional Positive Topline Data from Parts A and B of Phase 1 Clinical Trial of SKY-0515 at European Huntington's Disease Network and Enroll-HD 2024
The presentation highlights additional positive topline results from SAD/MAD study and preclinical data of SKY-0515, a novel small molecule designed to reduce both HTT and PMS1 proteins, two key drivers of Huntington's disease
